{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T10:11:03Z","timestamp":1760782263776},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2002,2,1]]},"DOI":"10.1093\/ndt\/17.2.204","type":"journal-article","created":{"date-parts":[[2002,7,26]],"date-time":"2002-07-26T22:28:32Z","timestamp":1027722512000},"page":"204-207","source":"Crossref","is-referenced-by-count":32,"title":["Calcimimetic agents and secondary hyperparathyroidism: treatment and prevention"],"prefix":"10.1093","volume":"17","author":[{"given":"William G.","family":"Goodman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2002,2]]},"reference":[{"key":"key\n\t\t\t\t20180110092250_R1","unstructured":"Nemeth EF. Calcium receptors as novel drug targets. In: Bilezikian JP, Raisz LG, Rodan GA, eds. Principles in Bone Biology. Academic Press, Inc., San Diego, 1996: 1019\u20131035"},{"key":"key\n\t\t\t\t20180110092250_R2","doi-asserted-by":"crossref","unstructured":"Silverberg SJ, Bone HG, III, Marriott TB et al. Short\u2010term inhibition of parathyroid hormone secretion by a calcium\u2010receptor agonist in patients with primary hyperparathyroidism. N Engl J Med1997; 337: 1506\u20131510","DOI":"10.1056\/NEJM199711203372104"},{"key":"key\n\t\t\t\t20180110092250_R3","doi-asserted-by":"crossref","unstructured":"Antonsen JE, Sherrard DJ, Andress DL. A calcimimetic agent acutely suppresses parathyroid hormone levels in patients with chronic renal failure. Rapid communication. Kidney Int1998; 53: 223\u2013227","DOI":"10.1046\/j.1523-1755.1998.00735.x"},{"key":"key\n\t\t\t\t20180110092250_R4","doi-asserted-by":"crossref","unstructured":"Goodman WG, Frazao JM, Goodkin DA et al. A calcimimetic agent lowers plasma parathyroid hormone levels in patients with secondary hyperparathyroidism. Kidney Int2000; 58: 436\u2013445","DOI":"10.1046\/j.1523-1755.2000.00183.x"},{"key":"key\n\t\t\t\t20180110092250_R5","unstructured":"Fox J, Lowe SH, Petty BA, Nemeth EF. NPS R\u2010568: a type II calcimimetic compound that acts on parathyroid cell calcium receptor of rats to reduce plasma levels of parathyroid hormone and calcium. J Pharmacol Exp Ther1999; 290: 473\u2013479"},{"key":"key\n\t\t\t\t20180110092250_R6","doi-asserted-by":"crossref","unstructured":"Brown EM. Four\u2010parameter model of the sigmoidal relationship between parathyroid hormone release and extracellular calcium concentration in normal and abnormal parathyroid tissue. J Clin Endocrinol Metab1983; 56: 572\u2013581","DOI":"10.1210\/jcem-56-3-572"},{"key":"key\n\t\t\t\t20180110092250_R7","doi-asserted-by":"crossref","unstructured":"Goodman WG, Salusky IB. Parathyroid gland function and the set point for PTH release: understanding the available data. Nephrol Dial Transplant1996; 11: 16\u201318","DOI":"10.1093\/ndt\/11.1.16"},{"key":"key\n\t\t\t\t20180110092250_R8","doi-asserted-by":"crossref","unstructured":"Goodman WG. Recent developments in the management of secondary hyperparathyroidism. Kidney Int2001; 59: 1187\u20131201","DOI":"10.1046\/j.1523-1755.2001.0590031187.x"},{"key":"key\n\t\t\t\t20180110092250_R9","unstructured":"Hammerland LG, Garrett JE, Hung BCP, Levinthal C, Nemeth EF. Allosteric activation of the Ca2+ receptor expressed in Xenopus laevis oocytes by NPS 467 or NPS 568. Mol Pharmacol1998; 53: 1083\u20131088"},{"key":"key\n\t\t\t\t20180110092250_R10","doi-asserted-by":"crossref","unstructured":"Kifor O, Moore FD, Jr., Wang P et al. Reduced immunostaining for the extracellular Ca2+\u2010sensing receptor in primary and uremic secondary hyperparathyroidism. J Clin Endocrinol Metab1996; 81: 1598\u20131606","DOI":"10.1210\/jc.81.4.1598"},{"key":"key\n\t\t\t\t20180110092250_R11","doi-asserted-by":"crossref","unstructured":"Schmitt CP, Huber D, Mehls O et al. Altered instantaneous and calcium\u2010modulated oscillatory PTH secretion patterns in patients with secondary hyperparathyroidism. J Am Soc Nephrol1998; 9: 1832\u20131844","DOI":"10.1681\/ASN.V9101832"},{"key":"key\n\t\t\t\t20180110092250_R12","doi-asserted-by":"crossref","unstructured":"Lane NE, Sanchez S, Modin GW et al. Parathyroid hormone treatment can reverse corticosteroid\u2010induced osteoporosis. Results of a randomized controlled clinical trial. J Clin Invest1998; 102: 1627\u20131633","DOI":"10.1172\/JCI3914"},{"key":"key\n\t\t\t\t20180110092250_R13","doi-asserted-by":"crossref","unstructured":"Gowen M, Stroup GB, Dodds RA et al. Antagonizing the parathyroid calcium receptor stimulates parathyroid hormone secretion and bone formation in osteopenic rats. J Clin Invest2000; 105: 1595\u20131604","DOI":"10.1172\/JCI9038"},{"key":"key\n\t\t\t\t20180110092250_R14","doi-asserted-by":"crossref","unstructured":"Ishii H, Wada M, Furuya Y et al. Daily intermittent decreases in serum levels of parathyroid hormone have an anabolic\u2010like action on the bones of uremic rats with low\u2010turnover bone and osteomalacia. Bone2000; 26: 175\u2013182","DOI":"10.1016\/S8756-3282(99)00263-X"},{"key":"key\n\t\t\t\t20180110092250_R15","doi-asserted-by":"crossref","unstructured":"Goodman WG. Calcimimetic agents for the treatment of hyperparathyroidism. Curr Opin Nephrol Hypertens2001; 10: 575\u2013580","DOI":"10.1097\/00041552-200109000-00005"},{"key":"key\n\t\t\t\t20180110092250_R16","unstructured":"Lindberg JS, Moe SM, Goodman WG et al. The calcimimetic AMG\u2010073 reduces parathyroid hormone (PTH), phosphorus (P), and calcium\u00d7phosphorus product (Ca\u00d7P) in patients with ESRD and secondary hyperparathyroidism. J Am Soc Nephrol2000; 11: 578 (Abstract)"},{"key":"key\n\t\t\t\t20180110092250_R17","unstructured":"Goodman WG, Hladik GA, Turner SA et al. Multiple doses of the calcimimetic, AMG\u2010073, reduce parathyroid hormone levels in a dose dependent manner in hemodialysis patients with secondary hyperparathyroidism. J Am Soc Nephrol2000; 11: 576 (Abstract)"},{"key":"key\n\t\t\t\t20180110092250_R18","doi-asserted-by":"crossref","unstructured":"Block GA, Hulbert\u2010Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium\u00d7phosphorus product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis1998; 31: 607\u2013617","DOI":"10.1053\/ajkd.1998.v31.pm9531176"},{"key":"key\n\t\t\t\t20180110092250_R19","doi-asserted-by":"crossref","unstructured":"Goodman WG, Goldin J, Kuizon BD et al. Coronary artery calcification in young adults with end\u2010stage renal disease who are undergoing dialysis. N Engl J Med2000; 342: 1478\u20131483","DOI":"10.1056\/NEJM200005183422003"},{"key":"key\n\t\t\t\t20180110092250_R20","doi-asserted-by":"crossref","unstructured":"Marchais SJ, Metivier F, Guerin AP, London GM. Association of hyperphosphataemia with haemodynamic disturbances in end\u2010stage renal disease. Nephrol Dial Transplant1999; 14: 2178\u20132183","DOI":"10.1093\/ndt\/14.9.2178"},{"key":"key\n\t\t\t\t20180110092250_R21","doi-asserted-by":"crossref","unstructured":"Wada M, Nagano N, Furuya Y et al. Calcimimetic NPS R\u2010568 prevents parathyroid hyperplasia in rats with severe secondary hyperparathyroidism. Kidney Int2000; 57: 50\u201358","DOI":"10.1046\/j.1523-1755.2000.00837.x"},{"key":"key\n\t\t\t\t20180110092250_R22","doi-asserted-by":"crossref","unstructured":"Chin J, Miller SC, Wada M et al. Activation of the calcium receptor by a calcimimetic compound halts the progression of secondary hyperparathyroidism in uremic rats. J Am Soc Nephrol2000; 11: 903\u2013911","DOI":"10.1681\/ASN.V115903"},{"key":"key\n\t\t\t\t20180110092250_R23","doi-asserted-by":"crossref","unstructured":"Li YC, Amling M, Pirro AE et al. Normalization of mineral ion homeostasis by dietary means prevents hyperparathyroidism, rickets and osteomalacia, but not alopecia in vitamin D receptor\u2010ablated mice. Endocrinology1998; 139: 4391\u20134396","DOI":"10.1210\/endo.139.10.6262"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ndt\/article-pdf\/17\/2\/204\/23371780\/170204.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,17]],"date-time":"2021-05-17T16:11:32Z","timestamp":1621267892000},"score":1,"resource":{"primary":{"URL":"http:\/\/academic.oup.com\/ndt\/article\/17\/2\/204\/1808890"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,2,1]]},"references-count":23,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2002,2]]},"published-print":{"date-parts":[[2002,2,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/17.2.204","relation":{},"ISSN":["1460-2385","0931-0509"],"issn-type":[{"value":"1460-2385","type":"electronic"},{"value":"0931-0509","type":"print"}],"subject":[],"published-other":{"date-parts":[[2002,2]]},"published":{"date-parts":[[2002,2,1]]}}}